Below are the most recent publications written about "Protein C" by people in Profiles.
-
Hollander JE. Drotrecogin alfa (activated) in septic shock. N Engl J Med. 2012 09 06; 367(10):968; author reply 969.
-
Li J, Carr B, Goyal M, Gaieski DF. Sepsis: the inflammatory foundation of pathophysiology and therapy. Hosp Pract (1995). 2011 Aug; 39(3):99-112.
-
Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, Paquette N, Thiyagarajan M, Deane R, Fernandez JA, Lane S, Zlokovic AB, Liu T, Griffin JH, Chow N, Castellino FJ, Stojanovic K, Cleveland DW, Zlokovic BV. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest. 2009 Nov; 119(11):3437-49.
-
Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, Riccardi L, Lancellotti S, Santoliquido A, Flore R, Pompili M, Rapaccini GL, Tondi P, Gasbarrini GB, Landolfi R, Gasbarrini A. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009 Oct; 51(4):682-9.
-
Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, Moretti E, Nguyen HB, Gunnerson KJ, Milzman D, Gaieski DF, Goyal M, Cairns CB, Ngo L, Rivers EP. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med. 2009 Jan; 37(1):96-104.
-
Gaieski D, Goyal M. The implementation of new therapies for severe sepsis: some questions raised by "early goal-directed therapy, corticosteroid, and recombinant human activated protein c for the treatment of severe sepsis and septic shock in the emergency department". Acad Emerg Med. 2006 Sep; 13(9):997-9; author reply 999-1000.
-
Deans KJ, Haley M, Natanson C, Eichacker PQ, Minneci PC. Novel therapies for sepsis: a review. J Trauma. 2005 Apr; 58(4):867-74.
-
Jennings I, Kitchen S, Woods TA, Preston FE. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin Thromb Hemost. 2005 Feb; 31(1):66-72.
-
Deans KJ, Minneci PC, Banks SM, Natanson C, Eichacker PQ. Substantiating the concerns about recombinant human activated protein C use in sepsis. Crit Care Med. 2004 Dec; 32(12):2542-3.
-
Deans KJ, Minneci PC, Eichacker PQ, Natanson C. The efficacy of drotrecogin alfa depends on severity of illness. Crit Care Med. 2004 Nov; 32(11):2347.